Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lowers Jupiter Fund Management to 'sell'

(Sharecast News) - Analysts at Canaccord Genuity downgraded Jupiter Fund Management to 'sell' from 'hold' on Wednesday, citing a weak earnings outlook and non-compelling capital returns. Canaccord said Jupiter's earnings outlook was poor, in its view, which it said was "not remarkable" in the UK traditional asset managers sector in itself, noting that it now expects underlying earnings per share to decline by 55% year-on-year in FY25 and 11% year-on-year in FY26.

The Canadian bank said its forecasts were predicated on -£4.0bn net outflows in FY25, followed by -£0.7bn net outflows in FY26 before turning to net inflows of £3.3bn in FY27. But it also said it sees downside risk to its net flow forecasts.

"Against the steep earnings decline, the capital returns policy does not provide a compelling offset, in our view," said Canaccord Genuity. "The ordinary dividend policy is 50% of pre-performance fee underlying earnings, which introduces significant volatility into the expected dividend return."

Canaccord, which lowered its target price on the stock from 78.0p to 60.0p, also doesn't expect to see further buybacks or special dividends through its forecast horizon.

"Assuming no multiple re-rating or de-rating, we forecast an average annual return for FY24A-26F of -29% p.a., which clearly looks unappealing," said the analysts.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.